ArticleNature communications2025

Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies.

Yan-Ruide Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.